Zobrazeno 1 - 4
of 4
pro vyhledávání: '"V V Strugov"'
Autor:
E A Stadnik, V V Strugov, T O Andreeva, Yu V Virts, A M Rumyantsev, Yu V Mirolyubova, P A Butylin, A Yu Zaritsky
Publikováno v:
Терапевтический архив, Vol 89, Iss 7, Pp 57-64 (2017)
Aim. To evaluate the efficacy and safety of the BR regimen containing bendamustine in patients with chronic lymphocytic leukemia (CLL) who have not previously received specific therapy. Subjects and methods. The results of the Russian prospective obs
Externí odkaz:
https://doaj.org/article/cd650e21d2374da8a7d8ff39b67fd7cc
Autor:
E A Stadnik, V V Strugov, T O Andreeva, Yu V Virts, Yu V Mirolyubova, P A Butylin, A Yu Zaritskiy
Publikováno v:
Современная онкология, Vol 18, Iss 5, Pp 33-35 (2016)
This trial has evaluated a systematic prospective analysis of the efficacy and safety of BR in CLL patients in the routine clinical practice. It included 179 patients with verified CLL diagnosis and the presence of the indications for initiation of t
Externí odkaz:
https://doaj.org/article/e9d31cf4381f45f4a0418436c5ced9c6
Autor:
A. S. Luchinin, V. V. Strugov
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 3, Pp 57-63 (2021)
The current strategy of chronic lymphocytic leukemia (CLL) treatment is based on genetic risk factors such as del(17p), TP53 mutations and/or unmutated variant of IGHV genes. Guidelines recommend the usage of targeted drugs, e.g. ibrutinib, in the fi
Externí odkaz:
https://doaj.org/article/b7db3b97fe1b4d6496dce2eabcac7f0a
Publikováno v:
Онкогематология, Vol 12, Iss 4, Pp 18-26 (2018)
Currently we are facing a revolution in therapy of chronic lymphocytic leukemia, related to the development of novel target drugs, which have markedly improved treatment results in all groups of patients. While inhibitors of Bruton’s tyrosine kinas
Externí odkaz:
https://doaj.org/article/0515099d9c794a59b7b3bae78f03019c